Literature DB >> 24972735

Effect of metabolic syndrome on the response to arterial injury.

Yuyang Fu1, Enrico A Duru1, Mark G Davies2.   

Abstract

BACKGROUND: Metabolic syndrome is now an epidemic in the United States population. Intimal hyperplasia remains the principal lesion in the development of restenosis after vessel wall injury. The aim of this study is to characterize the changes induced in wall morphology in the developing intimal hyperplasia within a murine model in the presence of diabetes (type 1) and metabolic syndrome.
METHODS: Control (wild type B6), Non Obese Diabetic, and metabolic syndrome (RCS-10) mice were used. The murine femoral wire injury model was used in which a micro wire is passed through a branch of the femoral and used to denude the common femoral and iliac arteries. Specimens were perfusion fixed and sections were stained with hematoxylin and eosin and Movat stains such that dimensional and compositional morphometry could be performed using an ImagePro system. Additional stains for proliferation and apoptosis were used.
RESULTS: In control mice, the injured femoral arteries develop intimal hyperplasia, which is maximal at 28 d and remains stable to day 56. Sham-operated vessels do not produce such a response. In diabetic mice, the intimal response increased 5-fold with a 2-fold increase in proteoglycan deposition, whereas in the metabolic syndrome mice there was a 6-fold increase in the intimal response and a similar increase in proteoglycan deposition. Collagen deposition was different with a 22-fold increase over control in collagen deposition in diabetes and a 100-fold increase over control in collagen deposition in metabolic syndrome as compared with the control injury mice. Maximal vascular smooth muscle cell (VSMC) proliferation was decreased in both diabetes and metabolic syndrome compared with controls, whereas early cell apoptosis in both diabetes and metabolic syndrome was sustained over a longer period of time compared with wild-type mice.
CONCLUSIONS: These data demonstrate that development of intimal hyperplasia is markedly different in diabetes and metabolic syndrome compared with controls, with an increase in collagen deposition, a reduction in VSMC proliferation, and an increase in early VSMC apoptosis. These findings suggest that preventative strategies against restenosis must be tailored for the diabetic and metabolic syndrome patients.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Metabolic syndrome; Response to injury; Vascular smooth muscle

Mesh:

Substances:

Year:  2014        PMID: 24972735      PMCID: PMC4134773          DOI: 10.1016/j.jss.2014.05.051

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  42 in total

1.  The metabolic syndrome in middle-aged men according to different definitions and related changes in carotid artery intima-media thickness (IMT) during 3 years of follow-up.

Authors:  K Wallenfeldt; J Hulthe; B Fagerberg
Journal:  J Intern Med       Date:  2005-07       Impact factor: 8.989

2.  Report on the workshop on diabetes and mechanisms of atherogenesis. September 17th and 18th, 1992, Bethesda, Maryland.

Authors:  G S Getz
Journal:  Arterioscler Thromb       Date:  1993-03

3.  Nitric oxide modulates vascular inflammation and intimal hyperplasia in insulin resistance and the metabolic syndrome.

Authors:  Joel E Barbato; Brian S Zuckerbraun; Marcus Overhaus; Kathleen G Raman; Edith Tzeng
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-02-25       Impact factor: 4.733

4.  Diabetes mellitus and experimental vein graft structure and function.

Authors:  M G Davies; J H Kim; M L Klyachkin; L Barber; H Dalen; E Svendsen; C C Carson; P O Hagen
Journal:  J Vasc Surg       Date:  1994-06       Impact factor: 4.268

5.  Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory.

Authors:  S Roy; R Sala; E Cagliero; M Lorenzi
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

Review 6.  The extracellular matrix in diabetic nephropathy.

Authors:  F N Ziyadeh
Journal:  Am J Kidney Dis       Date:  1993-11       Impact factor: 8.860

7.  Vascular growth factors and the development of macrovascular disease in diabetes mellitus.

Authors:  T Koschinsky; C E Bünting; R Rütter; F A Gries
Journal:  Diabete Metab       Date:  1987-07

8.  Heparan sulfate proteoglycan in the glomerular basement membrane in type 1 diabetes mellitus.

Authors:  R L Vernier; M W Steffes; S Sisson-Ross; S M Mauer
Journal:  Kidney Int       Date:  1992-04       Impact factor: 10.612

9.  Enhanced arterial intimal thickening after balloon catheter injury in diabetic animals accompanied by PDGF beta-receptor overexpression of aortic media.

Authors:  T Kanzaki; M Shinomiya; S Ueda; N Morisaki; Y Saito; S Yoshida
Journal:  Eur J Clin Invest       Date:  1994-06       Impact factor: 4.686

10.  Effect of chronic experimental diabetes on vascular smooth muscle function in rabbit carotid artery.

Authors:  D K Agrawal; S Bhimji; J H McNeill
Journal:  J Cardiovasc Pharmacol       Date:  1987-05       Impact factor: 3.105

View more
  3 in total

1.  A murine model of arterial restenosis: technical aspects of femoral wire injury.

Authors:  Toshio Takayama; Xudong Shi; Bowen Wang; Sarah Franco; Yifan Zhou; Daniel DiRenzo; Alycia Kent; Peter Hartig; Joshua Zent; Lian-Wang Guo
Journal:  J Vis Exp       Date:  2015-03-10       Impact factor: 1.355

2.  On-Site Classification of Pansteatitis in Mozambique Tilapia (Oreochromis mossambicus) using a Portable Lipid-Based Analyzer.

Authors:  John A Bowden; Stephen E Somerville; Theresa M Cantu; Matthew P Guillette; Hannes Botha; Ashley S P Boggs; Wilmien Luus-Powell; Louis J Guillette
Journal:  Anal Methods       Date:  2016-05-16       Impact factor: 2.896

3.  Nicorandil attenuates carotid intimal hyperplasia after balloon catheter injury in diabetic rats.

Authors:  Ying Qian Zhang; Feng Tian; Ying Zhou; Yun Dai Chen; Bo Li; Qiang Ma; Ying Zhang
Journal:  Cardiovasc Diabetol       Date:  2016-04-08       Impact factor: 9.951

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.